Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The combination of paclitaxel, doxorubicin, and cyclophosphamide is a standard neoadjuvant
(given before surgery) treatment for patients that have either inoperable or operable breast
cancer. This treatment can help shrink the tumors so they can be removed to help prevent the
cancer from spreading to other parts of the body. This study is being done to test the impact
of adding sunitinib as a single-agent (Segment 1), followed by sunitinib plus paclitaxel
(Segment 2), followed by doxorubicin and cyclophosphamide (Segment 3). We hope the addition
of sunitinib will make the treatment more effective, but we don't know if this is true.